Kimberly Shafer-Weaver's Publications

 

In addition to publications produced by the Health Analytics' scientific team, each member offers their own personal experience producing manuscripts for peer-reviewed journals and posters for conference presentations in numerous areas of expertise.

 

Back to Kimberly Shafer-Weaver

Back to Our Team

JOURNAL PUBLICATIONS

 

PEER REVIEWED PUBLICATIONS

 

Lo, B., A.D. Swafford, K.A. Shafer-Weaver, L.F. Jerome, L. Rakhlan, D.R. Mathern, C.A. Callahan, P. Jiang, L.J. Davison, H.E. Stevens, C.L. Lucas, J. White, R. von Borstel, J.A. Todd, and M.J. Lenardo.  2011.  Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status.  J. Transl. Med. 9:203.

 

Zeilinsky, R., J. Lyakhov, M. Hassan, M. Kuban, K.A. Shafer-Weaver, A. Gandjbakhche, and J. Capala.  2011. HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin. Cancer. Res. 17:5071-81.

 

Watkins, S.K., Z Zhu, E Riboldi, K.A. Shafer-Weaver, K.E.R. Stagliano, M.M. Sklavos,  S. Ambs, H. Yagita, and A.A. Hurwitz.  2011.  FOXO3A Programs Tumor-Associated Dendritic Cells To Become Tolerogenic in Human and Murine Prostate Cancer.  J Clin Invest. 121:1361-72.

 

Shafer-Weaver, K.A., M.J. Anderson, K. Stagliano, A. Malyguine, N.M. Greenberg and A.A. Hurwitz.  2009.  Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.  J. Immunol.  183:4848-52.

 

Shafer-Weaver, K.A., S.K. Watkins, M.J. Anderson, L. Draper, A. Malyguine, W. G. Alvord, N.M. Greenberg and A.A. Hurwitz.  2009.  Immunity to Murine Prostatic Tumors: Continuous Provision of T Cell Help Prevents CD8 T Cell Tolerance and Activates Tumor-Infiltrating Dendritic Cells. Cancer Res.  69:6256-64. 

 

Zaritskaya, L., K.A. Shafer-Weaver, M.K. Gregory, S.L. Strobl, M. Baseler and A. Malyguine.  2009. Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials. J Immunother. 32:186-94.

 

Anderson, M.J., K.A. Shafer-Weaver, N.M. Greenberg and A.A. Hurwitz.  2007.  Tolerization of Tumor-Specific T Cells Despite Efficient Initial Priming in a Primary Murine Model of Prostate Cancer. J Immunol. 178:1268-76.

 

Shafer-Weaver, K.A., S. Rosenberg, S. Strobl, G.W. Alvord, M. Baseler, and A. Malyguine.  2006.  Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.  J Immunother. 29:328-35.

 

Burkett, M.W., K.A. Shafer-Weaver, S. Strobl, M. Baseler and A. Malyguine.  2005. A novel flow cytometric assay for evaluating NK cell-mediated cytotoxicity. J. Immunother.8:396-402.

 

Lee, J.W., C.N. O’Brien, A.J. Guidry, M.J. Paape, K.A. Shafer-Weaver, and X. Zhao.  2005. Effect of a trivalent vaccine against Staphylococcus aureus mastitis lymphocyte subpopulations, antibody production and neutrophil phagocytosis.  Can. J. Vet. Res.  69:11.

 

Salcedo R., J.K. Stauffer, E. Lincoln, T.C. Back, J.A. Hixon, C. Hahn, K.A. Shafer-Weaver, A. Malyguine, R. Kastelein, and J.M. Wigginton.  2004.  IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells.  J Immunol. 173:7170.

 

Shafer-Weaver, K.A., T. Sayers, D. Kuhns, S.L. Strobl, M. Burkett, M. Baseler, and A. Malyguine. 2004.  Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J. Transl. Med.  2:31.

 

Malyguine, A., S. Strobl, K.A. Shafer-Weaver, T. Ulderich, A. Troke, M. Baseler, L. Kwak  and S. Neelapu. 2004. A Modified Human ELISPOT Assay to Detect Specific Responses to Primary Tumor Cell Targets.  J. Transl. Med. 2:9

 

Malyguine, A., K.A. Shafer-Weaver, E.G. Derby, M.W. Burkett, T. Sayers and M. Baseler. 2003. Granzyme B and IFN release by effector cells in cell-mediated cytotoxicity. Proc. Int. Cytokine Soc. D920C0295:105.

 

Shafer-Weaver, K.A., T. Sayers, S. Strobl,, E.D. Derby, T. Ulderich, M. Baseler and A. Malyguine. 2003.  The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl. Med. 1:14.

 

Shafer-Weaver, K.A., C.M. Corl, and L.M. Sordillo.  1998.  Elucidation of bovine CD4+ lymphocytes role in postpartum associated immunoregulation.  J. Dairy Sci. 82:1696.

 

Shafer-Weaver, K.A. and L.M. Sordillo.  1997.  Bovine CD8+ suppressor lymphocytes alter immune responsiveness during the periparturient period. Vet. Immunol. Immunopathol., 56:53.

 

Shafer-Weaver, K.A. and L.M. Sordillo.  1996.  Enhancing bactericidal activity of bovine lymphoid cells during the periparturient period. J. Dairy Sci, 79:1347.

 

Shafer-Weaver, K.A., G.M. Pighetti, and L.M. Sordillo.  1996.  Diminished mammary gland lymphocyte functions parallel shifts in trafficking patterns during the postpartum period.  Proc. Soc. Exp. Biol. Med., 212: 271.

 

 

PUBLISHED REVIEW ARTICLES               

 

Capitini, C.M., W.L. Redmond and K.A. Shafer-Weaver. 2012. Professional development session for early career scientists at SITC 2012.  J. Immunother. Cancer. 1:6.        

 

Shafer-Weaver, K.A., M.J. Anderson, A. Malyguine, and A. A. Hurwitz.  2007. T cell tolerance to tumors and cancer immunotherapy. Adv Exp Med Biol., 601:357-68.

 

Malyguine, A., S. Strobl, L. Zaritskaya, M. Baseler and K.A. Shafer-Weaver. 2007. New approaches for monitoring CTL activity in clinical trials. Adv Exp Med Biol., 601:273-84.

 

Paape, M.J., K.A. Shafer-Weaver, A.V. Capuco., K. Van Oostveldt, and C. Burvenich.  2000. Immune surveillance of mammary tissue by lymphocytes and phagocytic cells. Adv. Exp. Med. Biol. 480:259.

 

Sordillo, L.M., K.A Shafer-Weaver, and D.C. DeRosa.  1997.  Immunobiology of the mammary gland.  J. Dairy Sci., 80:1851.

© 2018 by Health Analytics, LLC    +1 (410) 997-3314    info@healthanalytic.com